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ABSTRACT 
Objective: Raloxifene hydrochloride (RLX) is widely used in the treatment of osteoporosis, but due to its extensive first pass metabolism bioavailability 
of RLX is remaining only 2%. In addition of that being from BCS class II, RLX has poor water solubility. Therefore the objective of present research work 
was to enhance solubility and dissolution rate of RLX by formulating inclusion complex with β cyclodextrin (β-CD) as a carrier.  
Methods: Inclusion complex was prepared by various methods like physical mixture, co-precipitation method and kneading method using different 
drug to carrier ratios (1:1, 1:2 and 1:3).  
Results: Inclusion complex prepared with co-precipitation method had shown 5.5 fold improvements in water solubility and significant increment 
in dissolution rate when compared with plain RLX. Optimized formulation was characterized by Fourier transform infrared spectroscopy, 
Differential scanning calorimetry, X-ray diffraction and Scanning electron microscopy studies for their compatibility, thermal analysis, crystallinity 
and surface morphology determination, respectively. Results of DSC and XRD study suggested the conversion of RLX from crystalline form to 
amorphous form. Stability studies showed stable formulation up to the period of 6 months. In vivo pharmacokinetic study was also conducted in 
wistar rats for optimized drug loaded inclusion complex that showed nearby two fold increments in drug bioavailability compared to plain drug 
suspension. 
Conclusion: From these studies, it can be concluded that solubility and dissolution rate of poorly soluble raloxifene could be remarkably increased 
by formulating into the inclusion complex with β-CD which results in significant improvement in bioavailability of poorly soluble RLX. 
Keywords: Bioavailability, Dissolution rate, BCS classification, Inclusion complex, Carrier. 
 
INTRODUCTION 
Poor water solubility has been recognized to almost half of the 
150,000 new molecular entities (NMEs), synthesized annually by 
pharmaceutical companies, and is also claimed to reduce the 
performance of more than 10% of successfully marketed drugs. 
Up to 40% of lipophilic drug candidates may fall short to reach 
market al. though exhibiting potential pharmacodynamic activities. 
Meanwhile, some lipophilic drugs on the market have to be 
administered at high doses. Therefore, various formulation 
strategies have been investigated to improve solubility and rate of 
dissolution followed by oral bioavailability of lipophilic drugs [1]. 
Osteoporotic fractures lead to morbidity and mortality. The 
occurrence of osteoporosis and the associated economic burden will 
rise as the population ages. Several antiresorptive agents currently 
available for prevention or treatment of postmenopausal osteoporosis 
include the bisphosphonates (Alendronate, Risedronate, and 
Ibandronate), calcitonin, estrogen, and the selective estrogen receptor 
modulator raloxifene (RLX) [2]. In the Multiple Outcomes of Raloxifene 
Evaluation (MORE) study, raloxifene 60 mg/day appreciably 
decreased the risk of new vertebral fractures by 30% and 55% 
compared with placebo, in women with and without prevalent 
vertebral fractures, respectively [3, 4]. 
Raloxifene is a selective estrogen receptor modulator (SERM) with a 
proven estrogen agonist action on bone that leads to an 
improvement in bone mass density, a reduction in bone turnover [3] 
and a decrease in vertebral fractures in post-menopausal women 
with osteoporosis [5]. Although it belongs to class II drug according 
to biopharmaceutical classification system (BCS), it has only 2% 
bioavailability. Hence it is essential to increase solubility and 
dissolution rate of raloxifene which may lead to enhancement in 
bioavailability through oral dosage form [6]. 
In the present study, inclusion complex was formulated to enhance 
solubility of drug by complexing with β–cyclodextrin (β-CD). 
Cyclodextrins (CDs), with lipophilic interior cavities and hydrophilic 
outer surfaces, are capable of interacting with a large variety of 
guest molecules to form noncovalent inclusion complexes. β-CD has 
been widely used in the early stages of pharmaceutical applications 
for the reason of its ready availability and cavity size suitable for the 
widest range of drugs [7]. 
In the present research work, inclusion complex of RLX with β-CD was 
prepared to study the effect of different methods (physical, co-
precipitation and kneading method) on drug’s aqueous solubility. The 
prepared inclusion complexes were studied for in vitro release, Fourier 
transform infrared spectroscopy (FTIR), differential scanning 
calorimetry (DSC), X-ray diffractometry (XRD) and scanning electron 
microscopy (SEM). Bioavailability enhancement in selected inclusion 
complex (optimized based on its improved solubility and dissolution 
rate) was checked by performing In vivo study for the determination of 
various pharmacokinetic parameters. The objective of this work was to 
improve solubility and dissolution rate followed by bioavailability of 
poorly soluble RLX by complexing drug with β-CD. 
MATERIALS AND METHODS 
Materials 
RLX was obtained as gift sample from Aarti drugs Pvt Ltd, Mumbai, 
India. β-CD was purchased from Merck specialities Pvt Ltd, Mumbai. 
All other reagents used in work were of analytical grade. 
Formulation of inclusion complex of RLX with β-CD 
The inclusive complex of RLX with β-CD was prepared by following 
methods. Formulation codes for all methods are given in table 1. 
Different ratios of RLX and β-CD (1:1, 1:2 & 1:3) were taken for the 
preparation of inclusion complexes for all methods. 
Physical mixture 
RLX with β-CD were mixed in a mortar and pestle for 1h with 
continuous trituration. Mixture was passed through sieve no. 80 and 
stored in desiccators over fused calcium chloride. 
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Co-precipitation method  
Accurately weigh quantity of drug and β-CD were dissolved in 
methanol and distilled water, respectively. Drug solution was added 
slowly to β-CD solution and mixture was stirred at room 
temperature for 1h followed by slowly evaporation on a boiling 
water bath for complete evaporation of solvents. The inclusion 
complex precipitated as a crystalline powder which was pulverized 
and passed through sieve no. 80 and stored in a desiccator having 
fused calcium chloride [8, 9].  
Kneading method 
Accurately weigh quantity of β-CD was triturated in the mortar 
containing little quantity of 50% methanol to get slurry like 
consistency. Drug was incorporated into the slurry and triturated 
further for 1h. Mixture was air dried at 25 °C for 24 h, pulverized 
and passed through sieve no. 80 and stored in desiccators over fused 
calcium chloride [8, 9].  
Characterization of inclusion complex 
Percentage yield 
The yield was calculated by dividing the weight of the collected 
inclusion complex with the weight of all the non-volatile 
components used for preparation of the inclusion complex.  
Percentage yield= Weight of inclusion complex recovered
Theoretical weight (drug+carrier)
 X 100 
Drug content 
Accurately weigh quantity of the inclusion complex (equivalent to 5 mg 
of RLX) was transferred to 50 ml volumetric flask. Volume was made up 
to the mark with buffer system (citro phosphate buffer pH 7.6 containing 
1% polysorbate 80). The absorbance of the solution was measured after 
suitable dilution at 288 nm against buffer system as blank using UV-
visible spectrophotometer (UV-1800, Shimadzu, Japan).  
Solubility study in water  
Excess amount of inclusion complex was added to 10 ml water in 
stopper volumetric flask followed by sonication for 10 min. Flasks 
were kept at 25±2.0o
Drug excipients compatibility studies of optimized batch  
C in an isothermal orbital shaker (MSW-132, 
MAC scientific Works Pvt Ltd, Delhi) for 24 h to reach equilibrium. 
The equilibrated samples were removed from shaker and 
centrifuged at 5000 rpm for 15 min using remi centrifuge (C-24 BL, 
Remi instruments Pvt Ltd, Mumbai) [10]. The water solubility profile 
of inclusion complex was determined by analyzing the supernatant 
spectroscopically at 288 nm.  
Drug excipients compatibility study was carried out by FTIR 
(IRAffinity-1, Shimadzu, Japan) for pure drug, β-CD, physical mixture 
and optimized inclusion complex to study interaction between drug 
and excipients. Sample was mixed with KBr in a ratio of 1:300 and 
FTIR spectrum was recorded in the range of 4000–400 cm-1using 
FTIR spectrophotometer [8-12].  
In vitro drug release 
Drug release from plain RLX suspension and optimized inclusion 
complex were determined in 900 ml citro phosphate buffer pH 7.6 
containing 1% of polysorbate 80 at 37±0.5 °C with a stirrer rotation 
speed of 75 rpm using USP dissolution test apparatus type II (TDT–
08L, Electrolab, Mumbai). RLX-β-CD inclusion complex was taken 
equivalent to 60 mg of RLX in a capsule shell [6]. Aliquots of 5 ml 
sample were withdrawn at predefined time interval with a pipette 
and replaced with fresh buffer at each time [13]. The samples were 
filtered through cellulose acetate membrane filter (0.45μm) and 
analyzed by using UV-Visible spectrophotometer at 288 nm. Each 
dissolution test was carried out in triplicate.  
DSC is widely used in thermal analysis to observe endothermic and 
exothermic reactions. It could be very useful in preformulation studies 
as it gives information about possible drug-excipients interactions in 
formulation. Thermograms of RLX, β-CD & optimized inclusion 
complex were obtained by using differential scanning calorimeter 
(DSC TA-60, Shimadzu, Japan). Samples were weighed directly in 
aluminum pan and scanned at 50-300 °C temperature under dry 
nitrogen atmosphere. Heating rate of 10 °C/min was used [14]. 
Differential scanning calorimetry  
XRD study can become useful tool to find out amorphous or 
crystalline form of formulations [13]. XRD study of RLX, β-CD, 
physical mixture & optimized inclusion complex was carried out by 
X Ray Diffractometer (Xpert Pro MPD, Panalytical, The Netherlands) 
where CuKα radiation wavelength of 1.5405 A
X-Ray diffraction studies  
o
Surface morphology study  
 was used as X-ray 
source. For the study, samples were placed in the glass sample 
holders and scanned from 2 ° to 60 ° at a scan angular speed 
(2θ/min) of 2 °/min with 40kv operating voltage and 30 mA current.  
The surface morphology and shape of solid particles can be studied 
by SEM [15]. Surface morphology of plain RLX and optimized 
inclusion complex were obtained by scanning electron microscope 
(JEOL JSM-5610LV, England). Prior to examination, the samples 
were mounted on to metal stubs using a double-sided adhesive tape 
under vacuum. Images were observed at various magnifications, 
operated with an acceleration voltage of 15 kV and working distance 
of 20 µm was maintained [16, 17].  
Stability study  
The selected formulation was subjected to stability studies as per 
ICH guidelines [18]. The samples were placed in vials and kept at 
25°C ± 2 °C/ 60% ± 5% RH ± SD and 40°C ± 2°C/ 75% ± 5% RH [16] 
using stability chamber (Macro scientific work Pvt Ltd, Delhi) over 
period of six months. The samples were analyzed for physical 
appearance and the drug content at the interval of 0, 15, 30, 60, 120 
& 180 days.  
In vivo Pharmacokinetic study in Wistar rats 
In vivo pharmacokinetic study was carried out for optimized 
formulations IC-6 and plain drug suspension to check the 
bioavailability of RLX, as per the protocol discussed underneath. 
Experimental animals  
The experimental protocol in the present study was approved by the 
Committee for the Purpose of Control and Supervision of Experiments 
on Animals (CPCSEA) and the Institutional Animal Ethics Committee 
(IAEC). Healthy female Wistar rats weighing 200-250g were used for 
the study [14]. Rats were housed in polypropylene cages, maintained 
under standardized condition (12 h light/dark cycle, 24 °C, 35-60 % 
humidity) and allowed free access to diet (Nav Maharashtra oil mills 
ltd, Pune) and purified drinking water [19, 20]. 
Bioanalytical method 
In the present research work, HPLC (UFLC, Shimadzu corporation, 
Japan) prominence liquid chromatographic system was used for 
chromatographic separation which is controlled by LC solution 
software (Version 1.24 Sp1, Shimadzu corporation, Japan). The 
system was equipped with Binary pump (LC 20AD version 1.10, 
Shimadzu corporation, Japan), a manual injector, a column (C18 250 
mm × 4.6 mm, 5 μm) (Luna, Phenominax, USA) and a photo diode 
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array (PDA) detector (SPD 20A version 1.08, Shimadzu corporation, 
Japan). The mobile phase used for separation is 67% 0.05M ammonium 
acetate buffer (pH was adjusted to 4.0 with glacial acetic acid) and 33% 
acetonitrile [14, 19, 21] which was delivered isocratically with a flow 
rate of 1 ml min−1
A glass capillary was inserted into retro orbital plexus under mild 
ether anesthesia for the withdrawn of blood samples (0.5 ml) at a 
time interval of predose, 0.25, 0.5, 1, 2, 4, 8, 12 and 24 h post dose. 
Blood samples were collected in micro centrifuge tubes containing 
anticoagulant. The plasma was separated immediately from 
aforementioned samples after centrifugation at 5,000 rpm at 4 °C for 
10 min and stored immediately at-20 °C until further analysis 
[19,22]. Samples were analyzed by standard HPLC method after 
standard sample extraction procedure. 
. The injection volume used was 20 μL and the analysis 
was carried out at wavelength of 288 nm [19, 22]. 
Standard sample treatment procedure  
Preparation of standard solution 
A series of standard solutions of RLX were prepared in methanol, in 
the range of 0.1-10 μg/ml. Samples were prepared by addition of 
standard solution of drug in methanol (50 μl) with acetonitrile (200 
μl) to eppendorf tube containing blank plasma (100 μl) [20]. This 
prepared mixture was treated as per the method given in sample 
extraction procedure. Final RLX concentrations in plasma were 
obtained 0.05-5 μg/ml. 
Sample extraction procedure 
Standard solution of drug in methanol and acetonitrile were added 
to the eppendorf tube containing plasma sample (volume as 
mentioned above) followed by meticulously vortex mixing (Macro 
Scientific Work Pvt Ltd, Delhi) for 30 sec. Centrifugation was carried 
out for the separation of denatured protein at 15,000 rpm for 10 min 
at-6 °C [19,20]. After centrifugation, aliquots of 20 μl of the filtered 
supernatant (0.45μm membrane filter) were injected into HPLC 
system and drug content was measured at 288 nm for analysis. 
Experimental design 
The animals were fasted at least 12 h prior to dose administrations and 
for 4 h after dosing with free access to water. Animals were divided into 
two groups each consisting of six animals. All animals were given 
different formulations group wise as described underneath [22].  
Group I: Control group (Plain RLX suspension in 0.5% w/v sodium 
CMC, 15 mg/kg, p. o.) 
Group II: Formulation (optimized batch IC-6, 15 mg/kg, p. o.) 
Pharmacokinetic data analysis 
PK solver add-in program for Microsoft Excel (version 1.0, China) 
was used for the estimation of Pharmacokinetic parameters. Various 
parameters like maximum plasma concentration (Cmax), time for 
achieving maximum plasma concentration (Tmax), area under curve 
[AUC]0-24 and 
Statistical analysis 
relative bioavailability (F) were determined. Each 
experiment was carried out in triplicate. 
The obtained data was statistical analyzed by one way analysis of 
variance (ANOVA) using student’s t–test. Graph Pad Instat 
program version 3.01 (Graph Pad Software, Inc. CA, USA) was 
utilized to determine the significance difference between 
formulations. The level of statistically significance was selected as 
less than p<0.05. 
RESULTS AND DISCUSSION 
Characterization of inclusion complex 
Percentage yield, drug content and water solubility 
Percentage yield, drug content and water solubility of prepared 
inclusion complexes are shown in table 2. 
Percentage yield of all batches were calculated and it was found that 
there was no significant difference in percentage yield of all nine 
batches. But it was also observed that first three batches of physical 
mixture showed more yield compared to other two methods. The 
fact for this may be easiness of physical mixture method to make 
inclusion complex where in co-precipitation method and kneading 
method, there might be chance of losing the product due to 
solidification of mixture. 
 
Table 2: Percentage yield, drug content and water solubility of all prepared batches 
Formulation codes Percentage yield (%) Drug content (%) Water solubility (mg/ml) 
IC-1 99.08±0.82 48.05±1.34 0.17±0.02 
IC-2 98.87±0.98 32.10±0.75 0.22±0.02 
IC-3 98.95±0.87 24.13±0.54 0.29±0.03 
IC-4 96.33±1.76 47.19±0.91 0.39±0.02 
IC-5 96.12±1.38 32.02±1.18 0.50±0.05 
IC-6 96.41±2.05 24.11±0.53 0.61±0.04* 
IC-7 97.61±0.72 46.74±1.08 0.28±0.03 
IC-8 97.24±1.03 31.62±1.12 0.41±0.04 
IC-9 96.68±1.14 23.88±0.24 0.48±0.02 
Plain drug solubility (mg/ml) 0.11±0.02 
 Value are expressed as mean±SD; n=3 (* p<0.05) 
 
There was no significant effect of different methods of preparation for 
inclusion complexes on drug content, but from the study it was noted 
that for a same method if ratio of drug to carrier is increased then there 
is increment in drug content which support the fact that more amount of 
carrier may accommodate larger amount of drug in a complex form. 
From the solubility study, it was observed that plain drug has 
0.11±0.02 mg/ml solubility in water. Water solubility is drastically 
increased in a range from 0.17±0.02 to 0.61±0.04 when plain drug 
was converted into complex form with β-CD. It was also noted that 
solubility of drug in physical method was significantly less compared 
with other two methods. Maximum drug solubility was found in 
batch IC-6 prepared by co-precipitation method with drug: carrier 
ratio 1:3, which was found to be 5.5 fold more than plain drug that 
showed significant difference in comparison with plain drug 
suspension (p<0.05). Therefore based on solubility study batch IC-6 
was selected for further study.  
Drug excipients compatibility study 
Drug excipients compatibility study was carried out by FTIR for 
optimized inclusion complex IC-6 as shown in fig. 1. From the 
compatibility study it was observed that characteristic peaks of drug 
i.e. 945.12 cm-1 (Benzene ring), 1456.26 cm-1 (-S-benzothiophene), 
1600.92 cm-1 (-C-O-C-stretching) and 1647.21 cm-1 (C=O stretching) 
in inclusion complex IC-6 was found to be nearby similar with plain 
drug spectra. Thus, it was revealed that there was no significant 
physiochemical interaction between drug and β-CD was found when 
formulating inclusion complex. This result indicates compatibility 
between drug and carrier. From the result, it was found that 
pronounced enhancement in dissolution rate up to 93.46±0.26 % is 
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shown by RLX: β-CD inclusion complex compared to that of 
50.39±0.39 % by pure drug after 150 min. This is because of higher 
hydrophilicity and wetting property of β-CD. The results of the 
statistical analysis indicated significant dissolution rate 
enhancement of RLX from RLX: β-CD inclusion complex (p<0.05) 
compared with pure RLX. Optimized inclusion complex IC-6 also 
showed significant enhancement (p<0.05) in dissolution rate 
compared to previously carried out study by Patil PH et al. 
(84.47±0.84 
 
% drug release from RLX: Hydroxypropyl β-CD 
inclusion complex) [6]. 
 
Fig. 1: FTIR spectra of (A) Raloxifene HCL, (B) β-cyclodextrin, 
(C) Physical mixture and (D) optimized inclusion complex of 
RLX with β-CD (IC-6) 
 
In vitro drug release study was carried out between plain drug and 
optimized inclusion complex IC-6 as shown in fig. 2.  
In vitro drug release 
DSC measurements offer a close look at the crystallization and 
thermal behaviour of the inclusion complex formulations. The DSC 
thermograms of RLX, β-CD and inclusion complex of RLX with β-CD 
are shown in fig. 3. 
Differential scanning calorimetry 
Thermograms of RLX and β-CD showed endothermic peaks at 
272.92 °C and 117.79 °C corresponding to their melting points, 
respectively. Thermogram of optimized inclusion complex showed 
the presence of β-CD peak in hydrated form at 96.21 °C whereas 
broad peak of drug was observed at 273.30 °C suggesting the 
conversion of RLX from crystalline to amorphous form or 
solubilization of drug into melted carrier. 
 
 
Fig. 2: Dissolution profile of plain RLX suspension & inclusion 
complex (IC-6), * p<0.05 
 
 
Fig. 3: DSC Thermogram of (A) Raloxifene HCL, (B) β-
cyclodextrin and (C) Optimized inclusion complex (IC-6) 
Shah et al. 




Fig. 4: XRD patterns of (A) Raloxifene HCL, (B) β-cyclodextrin (C) 
Physical mixture and (D) Optimized inclusion complex (IC-6) 
 
Diffraction spectrum of drug and physical mixture of RLX & β-CD 
showed distinct peaks at 2θ scale, which was indicating the 
crystalline nature of drug. In case of optimized inclusion complex 
XRD pattern, there was a considerable reduction in relative 
integrated intensity of all peaks and no distinct peak of drug was 
observed throughout the 2θ scale.  
X-Ray diffraction studies 
XRD studies were performed in conjugation with DSC to verify the 
reduction of crystallinity of RLX. As shown in fig. 4, the X ray 
diffraction patterns were recorded for pure drug, β-CD, physical 
mixture and inclusion complex of RLX with β-CD.  
 
This finding was supported with results obtained from DSC studies. 
Therefore it can be concluded that RLX drug is completely converted 
into amorphous state when formulated in inclusion complex with β-




Fig. 5: SEM image of (A) Raloxifene HCL and (B) Optimized 
inclusion complex (IC-6) 
 
Surface morphology study 
As shown in fig. 5, scanning electron microscopic photograph of 
plain drug showed longer crystal with specific morphology, whereas 
for optimized RLX and 
In the present work, plain drug suspension and optimized batch IC-6 
were administered orally to female Wistar rats followed by 
determination of various pharmacokinetics parameters. 
Pharmacokinetic parameters of formulations was calculated and 
shown in table 4. 
β-CD inclusion complex a decrease in 
crystallinity was observed. This confirms complexation of drug with 
carrier β-CD attributed due to the conversion of amorphous form of 
drug in inclusion complex. 
Stability study 
As shown in table 3, stability data showed insignificant change in 
physical appearance and drug content of formulation in both 
stability conditions compared with initial observation of same batch. 
Thus, it was revealed that there is no significant physiochemical 
interaction between drug and excipients even after six months of 
storage period which indicate compatibility between them.  
In vivo pharmacokinetic study 
RLX being a BCS-II drug having very less aqueous solubility and also has 
extensive first pass metabolism, which results in a low oral 
bioavailability of drug. Therefore, a trial was made to increase solubility 
followed by bioavailability using concept of complexation method. 
 
Table 3: Stability study data for optimized inclusion complex (IC-6) 
Time (days) 25⁰C±2⁰C/60%±5% RH 40⁰ C±2⁰C/75%±5% RH 
Physical appearance Drug content Physical appearance Drug content 
0 Yellow free flowing Powder 24.11±0.53 Yellow free flowing Powder 24.11±0.53 
15 24.10±0.12 24.10±0.37 
30 24.08±0.75 24.12±0.52 
60 24.09±0.44 24.06±0.21 
120 24.05±0.36 23.98±0.11 
180 24.00±0.33 23.95±0.17 
 Value are expressed as mean±SD; n=3 
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Table 4: Comparative study of the pharmacokinetic parameters of optimized batch IC-6 and plain drug suspension 









±SD t1/2 F  (h)±SD 
Plain RLX suspension 39.52±4.44 8 452.46±25.65 7.61±0.34 -- 
IC-6 83.49±4.35* 6 878.64±39.22* 8.75±0.14 1.94 
 Value are expressed as mean±SD; n=3, F–Relative bioavailability, *p<0.05 compared with plain RLX suspension 
 
 
Fig. 6: Plasma concentration versus time profile of the 
optimized IC-6 and plain drug suspension 
 
Fig. 6 showed higher Cmax for optimized batch IC-6 (83.49±4.35 
ng/ml) at 4 h with respect to plain drug suspension (39.52±4.44 
ng/ml) at 8 h. As shown in table 4, the [AUC]0-24 of IC-6 was found 
878.64±39.22ng*h/ml in comparison of plain drug suspension 
452.46±25.65 ng*h/ml and was found statistically significance 
(p<0.05). This result may be attributed due to remarkable 
improvement in solubility and dissolution rate of optimized 
inclusion complexes than the plain drug. Elimination half-life (t1/2
CONCLUSION 
) 
of inclusion complex was also found higher than drug suspension. All 
these result showed nearby two fold increments in bioavailability of 
drug in case of drug loaded inclusion complex which confer its 
potential for improved oral delivery of RLX. 
Co-precipitation method was successfully employed to prepare stable 
RLX and β-CD inclusion complex. Lipophilic inner cavities and 
hydrophilic outer surfaces of cyclodextrins are able for interactions with 
a huge range of guest molecules to form non covalent inclusion 
complexes with drug molecules. Compared to plain drug, inclusion 
complex had shown 5.5 fold improvements in water solubility and 
significant enhancement in dissolution rate of drug. In complex 
formation, drug was converted into amorphous form which was 
confirmed by XRD and DSC studies. In vivo pharmacokinetic study of 
optimized inclusion complex showed nearby two fold increments in 
bioavailability of drug compared to plain drug suspension. Therefore, it 
can be concluded that even at large scale production, inclusion complex 
can be potentially exploited in improving water solubility and 
dissolution rate followed by bioavailability of poorly soluble raloxifene.  
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